Which Japanese pharma companies are leading AI adoption?

Takeda, Chugai, and Daiichi Sankyo have disclosed the most detailed AI integration plans. Takeda reports 63% active user adoption as of March 2024; Chugai reports active users exceeding 60%. Astellas and Eisai have disclosed less detail, and mid-tier firms have made minimal disclosure.

What are the main business areas where pharma firms are using AI?

Primary focus is drug discovery (ADCs, AI-driven discovery platforms, clinical development) and operational efficiency (manufacturing equipment maintenance, inventory optimization, inventory forecasting). Takeda emphasizes transformation across the entire value chain from target exploration to commercialization. Sales and marketing applications are rare among domestic firms, unlike foreign peers.

What risks do companies say AI poses?

Takeda, Chugai, and Daiichi Sankyo cite overestimation of AI capability, unclear decision responsibility, and unintended disclosure of confidential information. Daiichi Sankyo specifically warns that delayed response to AI innovation may result in loss of R&D advantage and reduced competitiveness.

Back to articlesTop Companies' AI Moves

Top Companies' AI Moves

Japanese pharmaceutical companies are embedding AI across research, manufacturing, and operations, with adoption rates now a competitive differentiator—and laggards risk losing R&D advantage by 2030.

Top Companies AI — Japan (1/2)1d ago6 min read

Key takeaway

Japan's largest pharmaceutical companies have moved AI from pilot projects to company-wide platforms, with Takeda and Chugai reporting that a majority of staff now use AI daily in routine work. Firms explicitly identify AI as a safeguard against R&D obsolescence and link adoption rates to future competitiveness. The gap between early adopters and slower-moving peers is already substantial, and leadership expects that by 2030, uneven AI investment will translate into measurable differences in growth.

Summaries like this, in your inbox every morning.

3 Key Points

What happened
Major domestic pharma firms—Takeda, Chugai, Daiichi Sankyo, Shionogi—have disclosed active AI deployment in 2025 annual filings. Takeda reports 63% of employees actively using generative AI tools as of March 2024, up 16 percentage points year-on-year; Chugai reports active users exceeding 60%. Firms are integrating AI into drug discovery platforms, clinical development, manufacturing forecasting, and inventory optimization.
Why it matters
Takeda, Chugai, and Daiichi Sankyo now treat AI as a competitive moat rather than an IT project—explicitly linking it to maintaining research superiority and avoiding performance decline. Daiichi Sankyo warns in its filing that 'delay in responding to AI technological innovation may result in loss of advantage in R&D and reduced competitiveness.' The gap between leaders (Takeda, Chugai, Bristol Myers Squibb at ~80% adoption) and mid-tier peers (Astellas, Eisai) is wide and widening, suggesting by 2030 the difference may appear as growth disparity.
What to watch
Takeda and Chugai emphasize AI integration across the entire value chain—from target discovery through commercialization—as a transformation tool for decision-making, not just efficiency. Takeda, Otsuka Holdings, and Kyowa Kirin are prioritizing workforce readiness (Otsuka launched a digital academy in July 2024; Kyowa is training digital project planners), signaling that human capability, not AI itself, is now the bottleneck.

FAQ

Which Japanese pharma companies are leading AI adoption?: Takeda, Chugai, and Daiichi Sankyo have disclosed the most detailed AI integration plans. Takeda reports 63% active user adoption as of March 2024; Chugai reports active users exceeding 60%. Astellas and Eisai have disclosed less detail, and mid-tier firms have made minimal disclosure.
What are the main business areas where pharma firms are using AI?: Primary focus is drug discovery (ADCs, AI-driven discovery platforms, clinical development) and operational efficiency (manufacturing equipment maintenance, inventory optimization, inventory forecasting). Takeda emphasizes transformation across the entire value chain from target exploration to commercialization. Sales and marketing applications are rare among domestic firms, unlike foreign peers.
What risks do companies say AI poses?: Takeda, Chugai, and Daiichi Sankyo cite overestimation of AI capability, unclear decision responsibility, and unintended disclosure of confidential information. Daiichi Sankyo specifically warns that delayed response to AI innovation may result in loss of R&D advantage and reduced competitiveness.

Discussion

No comments yet. Be the first to share your thoughts!

Arista Networks' balance sheet revealed a buildup of AI chip orders and deferred revenue months before its stock surged 76%, showing how close readers of financial details could have spotted the boom.

Top Companies AI — US (2/2)7h ago

Thermo Fisher Scientific is showcasing AI-powered mass spectrometry tools and integrated laboratory solutions at BIO 2026, positioning itself as a single partner for drug development from discovery through manufacturing.

Top Companies AI — US (2/2)7h ago

Salesforce launches Help Agent, a prebuilt AI customer service tool that charges based on resolved issues rather than usage metrics, becoming available in July 2026.

Top Companies AI — US (2/2)7h ago

CFOs warn that AI success in finance requires heavy investment in employee training, not just technology—but most companies spend 93% on tech and only 7% on people.

Top Companies AI — US (2/2)7h ago

Life sciences executives gather to argue that AI agents need a trustworthy data foundation before deployment—not the other way around.

Top Companies AI — US (2/2)7h ago

Corning, a century-old glassmaker, has become a major AI infrastructure winner as hyperscalers lock in long-term fiber and optical equipment deals to power sprawling data centers.

Top Companies AI — US (2/2)7h ago

Stay ahead with AI news

Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.

Get Started Free

Free · takes 30 seconds · unsubscribe anytime

5 minutes a day. The AI essentials.

200+ sources · Email / LINE / Slack

Get it free →

Japanese pharmaceutical companies are embedding AI across research, manufacturing, and operations, with adoption rates now a competitive differentiator—and laggards risk losing R&D advantage by 2030.

Key takeaway

3 Key Points

FAQ

Discussion

Related Articles

Arista Networks' balance sheet revealed a buildup of AI chip orders and deferred revenue months before its stock surged 76%, showing how close readers of financial details could have spotted the boom.

Thermo Fisher Scientific is showcasing AI-powered mass spectrometry tools and integrated laboratory solutions at BIO 2026, positioning itself as a single partner for drug development from discovery through manufacturing.

Salesforce launches Help Agent, a prebuilt AI customer service tool that charges based on resolved issues rather than usage metrics, becoming available in July 2026.

CFOs warn that AI success in finance requires heavy investment in employee training, not just technology—but most companies spend 93% on tech and only 7% on people.

Life sciences executives gather to argue that AI agents need a trustworthy data foundation before deployment—not the other way around.

Corning, a century-old glassmaker, has become a major AI infrastructure winner as hyperscalers lock in long-term fiber and optical equipment deals to power sprawling data centers.

Stay ahead with AI news